The poster entitled “Optimization of Transduction Conditions With GMP Like Lentiviral Vectors For The Gene Therapy Of Piruvate Kinase Deficiecy” was presented at European Hematology Association congress hold in Madrid from 22nd to the 25th of June.

The authors of these posters are:

  • Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)
  • Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
  • Unidad Mixta de Terapias Avanzadas. Instituto de Investigación Sanitaria Fundación Jiménez
  • VIVEbiotech (responsible for the manufacturing of Lentiviral vectors)

As shown in the poster, this work has been financed with the support of the USA-based leader Company in Gene Therapy, Rocket Pharma.